Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Changing treatment landscape of AML

Claudio Cerchione • 16 Sep 2020
SOHO Italy 2020
Leukemia CPX-351

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, updates us on novel therapies in acute myeloid leukemia (AML) and the evolving treatment landscape. Dr Cerchione discusses the use of CPX-351 in patients with secondary AML as well as the use of combination therapies to improve the outcomes of patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Claudio Cerchione

The role of patient preference in selecting treatment administration routes in multiple myeloma
1:35
The role of patient preference in selecting treatment administration routes in multiple myeloma
Claudio Cerchione • 23 Sep 2026
Advances in myeloma treatment: quadruplets, CAR T-cell therapy and bispecific antibodies
4:55
Advances in myeloma treatment: quadruplets, CAR T-cell therapy and bispecific antibodies
Claudio Cerchione • 23 Sep 2026
Patient satisfaction with subcutaneous isatuximab in myeloma: IRAKLIA and IZALCO
2:02
Patient satisfaction with subcutaneous isatuximab in myeloma: IRAKLIA and IZALCO
Claudio Cerchione • 23 Sep 2026
Looking forward to the second edition of the MYELOMAS international meeting
2:40
Looking forward to the second edition of the MYELOMAS international meeting
Claudio Cerchione • 13 Oct 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals